Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (3149)	11/8/2000 3:16:51 PM
From: DanZ	Read Replies (3) \| Respond to of 5582

Value? What do you know about the value of this company? Your opinion appears to be based on an uninformed supposition that zinc isn't effective against the common cold. The fact of the matter is there is more to this company than Zicam. Do you have any estimates for gum sales next quarter? How about the profit on gum next quarter? Have you read their press releases concerning "significant" growth in the gum operations "very soon"? What do you think that means? Your opinion of zinc and the common cold is wrong too. Here are some links so you can educate yourself. Theory that relates zinc to the common cold afpafitness.com Bruce Korant, PhD, of Du Pont Chemicals showed in Nature in 1974, that Zn2+ ions were strongly antirhinoviral. Others have shown that Zn2+ ions help T-cell lymphocytes release large amounts of interferon-gamma, a powerful antiviral agent. Other functions of Zn2+ ions helpful in treating or curing common colds include anti-inflammatory activities, destruction of histamine, stabilization of cell plasma membranes (prevents cell leakage, congestion and runny nose), and stimulates T-cell lymphocytes into action. Theory linking the rhinovirus to the ICAM-1 receptors www-micro.msb.le.ac.uk More research linking ICAM-1 to the rhinovirus hsc.wvu.edu Theory relating the rhinovirus to ICAM-1 receptors and the relationship of zinc to ICAM-1 mothernature.com To cause a cold, the virus needs to latch onto a cell structure called ICAM-I. Zinc ions, however, cut off viral access to ICAM-1, thus inhibiting the cold virus' proliferation. Relationship between zinc and the rhinovirus proven in vitro 164.195.100.11. It has been established in vitro that zinc ions can inhibit replication of a few of the many antigenically different rhinoviruses. It has been established that zinc can provide an astringent and decongestant effect in common cold treatment. Zinc inhibits the release of histamine from mast cells and basophils. But it can now be disclosed that the low dosages of zinc and the method of application only brings temporary relief, perhaps because natural circulation removes zinc ions from the locus of the treatment more rapidly than the low application rate of zinc ions by the dosages replaces them. Because it has been established in vitro that zinc ions can inhibit replication of rhinoviruses, one may theorize that a low dosage of zinc may produce a zinc ion concentration that may or may not reach antiviral concentrations and that a method of application that does not maintain a sufficiently high level of zinc ions in the locus of treatment would not prevent continued viral replications. Zicam corrects this situation by maintaining a constant level of zinc ions on the ICAM receptor. At any rate, the issue isn't whether a handful of biased short sellers think Zicam works. It is already proven that Zicam works in three double-blind placebo-controlled clinical studies, two of which were independent and published in a peer reviewed medical journal by reputable physicians and researchers. The issue is whether the company makes a profit on Zicam and their gum operations. You apparently don't even have a clue about the gum operations and you don't know how sales of Zicam are going this quarter. If you did, you wouldn't be short. Call some buyers in the retail channel and talk to them. Find someone who has access to IRI marketing data. You will learn that Zicam is selling very well right now. Regardless, the gum business is getting ready to bite you.

To: Anthony@Pacific who wrote (3149)	11/8/2000 6:24:38 PM
From: StockDung	Read Replies (1) \| Respond to of 5582

about what time did stockdung post? Subject: Ride The Wave Of Fortune Date: 3/10/98 6:41 AM Eastern Standard Time From: Videogo Message-id: <19980310114101.GAA03926@ladder02.news.aol.com> Guy Quigley may have seen much of his wealth evaporate in the past month, but it's business as usual... in February he issues a 1997 financial report that most CEOs could only dream about - sales shoot through the stratosphere, climbing from $5 million in 1996 to $70 million last year. Earnings soar, beating expectations (remember, Quigley had forecast earnings of $1.32 per share, compared with 10 cents per share in 1996)... Guy beat that... making $1.43 per share! Not bad for a little "guy" with one product and 14 employees! Only one problem... Guy tells us that a mild winter will result in 1st quarter revenues being significantly lower than consesus, with 1998 overall revenues being affected as well. Should we on this board forget this past year's 1,300 percent growth? Guy can't be too depressed about his wealth... two years ago, some of us on this board bought into the stock when it was trading below $1 a share!! Keep in mind, Quigley's ZIGG lozenge continues to have higher sales in US drug stores than Halls, Ricola or Ludens. It has created an entire new category of wannabes, none of which can actually duplicate Guy's gluconate-glycine formula. Warner-Lambert's imitation "Zinc Defense" isn't even on the list of approved FDA substances to be taken internally! Cold-Eeze may be hard pressed to maintain its 5-to-1 sales lead, but I say it's a buy at any price under 20... Our biggest test: how to sustain Wall Street's interest in a one-product firm whose revenues will rise and fall with the severity of the cold season. Quigley shareholdres should not be chasing after the immediate profit... I'm sure Guy wouldn't mind shedding his company's reputation as a "health care tidal wave" and replacing it with the image of a good, solid investment.